Skip to content
close icon

Severe Alopecia Areata

NO LONGER ACCEPTING APPLICATIONS
Published on:
October 3, 2024
Sign-up Expiration:
Updated:
Topics:
Balding
Hair Loss
Women's Health
Men's Health
Dr. Nicole Seminara
Locations:
Huntersville, NC
Dr. Nicole Seminara

AbbVie developed a JAK inhibitor, Upadacitinib, which when given systemically may address the current needs for adults and adolescents with severe Alopecia Areata. Upadacitinib is a selective and reversible JAK inhibitor which received approval for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, atopic dermatitis (AD), ulcerative colitis, and Crohn's disease and is also being developed for the treatment of other immune-mediated inflammatory diseases, including skin conditions.

View Additional Information
View Clinical Trial Attachment
Sign Up NowExpired - View Other Trials
ENDED

Other Enrolling Clinical Trials

View All Enrolling Trials
Adults with Moderate-to-Severe Plaque Psoriasis and Obesity

This study to see if weight loss improves plaque psoriasis

View Trial
Severe Alopecia Areata

This study is to evaluate efficacy and safety of Upadacitinib (Rinvoq) in adult and adolescent subjects with severe Alopecia Areata (AA)

View Trial
Chronic Kidney Disease

A study to evaluate quarterly and monthly TOUR006 in participants with Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein.

View Trial
Asthma Clinical Trial - TEVA

A study to evaluate the efficacy and safety of Fluticasone Propionate/Albuterol Sulfate fixed-dose combination on Severe Asthma Exacerbations in patients.

View Trial
Migraine Study for Adolescents 12-17 years

A study to evaluate the efficacy and safety of IV Eptinezumab in adolescents (12-17 years) for the preventive treatment of chronic migraines.

View Trial
Heart Failure with Reduced Ejection Fraction

Study to evaluate the efficacy, safety and tolerability of JTT‑861 administered in subjects with Heart Failure with Reduced Ejection Fraction.

View Trial

Sign-Up, Make an Appointment, or Receive More Information

Thank you for your interest in our clinical research trials. Please enter your contact information below and someone will reach out to you shortly to see if you qualify. You can also call us at 1-800-785-3150 or email participate@onsiteclinical.com

By submitting this form, you are consenting to receive marketing emails from: OnSite Clinical Solutions, LLC, 11220 Elm Lane Suite 200 Charlotte, NC 28277, and will be able to revoke your consent to receive emails at any time.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.